Excluding Greater China, MSD gains rights for developing, manufacturing and commercialising the therapy globally. Credit: Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

MSD has entered an exclusive licence agreement with Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the investigational oral small molecule lipoprotein(a) [Lp(a)] inhibitor, HRS-5346.

Currently in a Phase II trial in China, the therapy is intended to address cardiovascular diseases associated with elevated Lp(a) levels.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

MSD will pay Hengrui Pharma $200m upfront, up to $1.77bn in development, regulatory and commercial milestones, and royalties on net sales if the therapy gains approval.

MSD secured global rights to develop, manufacture and commercialise HRS-5346 from Hengrui, excluding Greater China.

Closure is anticipated in the second quarter of 2025.

MSD will incur a pre-tax charge of $200m – $0.06 for each share – which will be reflected in both generally accepted accounting principles (GAAP) and non-GAAP outcomes, upon the closure of the transaction.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Hengrui Pharma chief strategy officer and executive vice-president Dr Frank Jiang stated: “We believe MSD’s clinical expertise and global scale will help accelerate the development of HRS-5346 and potentially provide more patients with an additional option to reduce their risk of atherosclerosis.”

Lp(a) is generated in the liver and is a key contributor to cholesterol and fat transport in the bloodstream.

High levels of Lp(a) can lead to the formation of atherosclerotic plaques, increasing the risk of serious cardiovascular events such as heart attacks and strokes.

MSD Research Laboratories president Dr Dean Li stated: “Elevated blood concentrations of Lp(a) provide a well-documented risk factor for atherosclerotic cardiovascular disease, affecting as many as one in five adults globally.

“HRS-5346, an investigational oral small molecule inhibitor of Lp(a) formation, is an important addition that expands and complements our cardio-metabolic pipeline.”

In March 2025, MSD announced the opening of a new $1bn facility in Durham, North Carolina, expanding its vaccine manufacturing capabilities.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact